Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $5.00 price objective on the stock. D. Boral Capital’s price target would suggest a potential upside of 385.44% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research report on Thursday, January 23rd.

Hoth Therapeutics Trading Up 3.0 %

NASDAQ:HOTH opened at $1.03 on Monday. The stock has a market capitalization of $7.11 million, a PE ratio of -0.78 and a beta of 0.84. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80. The firm has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $1.01.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. On average, equities analysts predict that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC boosted its stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 95,946 shares of the company’s stock after buying an additional 13,038 shares during the period. Geode Capital Management LLC owned approximately 1.39% of Hoth Therapeutics worth $72,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.